Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $317.3 million.

  • Akebia Therapeutics' Total Non-Current Liabilities rose 2551.29% to $317.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $317.3 million, marking a year-over-year increase of 2551.29%. This contributed to the annual value of $264.7 million for FY2024, which is 47.57% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Total Non-Current Liabilities of $317.3 million as of Q3 2025, which was up 2551.29% from $302.2 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Total Non-Current Liabilities registered a high of $436.1 million during Q1 2022, and its lowest value of $246.0 million during Q1 2024.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $302.2 million (2025), whereas its average is $314.5 million.
  • Per our database at Business Quant, Akebia Therapeutics' Total Non-Current Liabilities plummeted by 3503.97% in 2023 and then surged by 2551.29% in 2025.
  • Akebia Therapeutics' Total Non-Current Liabilities (Quarter) stood at $371.1 million in 2021, then decreased by 9.71% to $335.1 million in 2022, then decreased by 21.4% to $263.4 million in 2023, then increased by 0.48% to $264.7 million in 2024, then increased by 19.9% to $317.3 million in 2025.
  • Its Total Non-Current Liabilities was $317.3 million in Q3 2025, compared to $302.2 million in Q2 2025 and $278.4 million in Q1 2025.